The global acne therapeutics market is expected to grow at a CAGR of XX% during the forecast period 2016-2021. The market was estimated to be USD XX million in 2015 and is forecasted to reach USD XX million by 2021.
Acne is one of the most common skin disorders in the United States, currently, affecting almost 40 – 50 million Americans, annually. The American Academy of Dermatology states that approximately 85% of people between the ages of 12 and 24 years’ experience at least minor acne. The costs associated with the treatment of acne currently exceed USD 3 billion. The acne market awaits a blockbuster drug; most of the current pipeline products consist of combination products with very few first-in-class molecules. Emerging products are also not significantly different from the current monotherapies.
Global Acne Therapeutics - Market Dynamics
The report details several factors driving and restraining the market, some of which are discussed below.
The global acne therapeutics market has been segmented by treatment into therapeutics and other treatments. The therapeutics segment is further segmented into antibiotics (erythromycin and clindamycin), retinoid (adapalene, tazaroteen, tretinoin and isotretinoin), combination medications, anti-inflammatory, hormonal agents and other agents (azelaic acid and resorcinol). Other treatments include laser and light therapy, cosmetic procedures and acne scar treatment. The market has been geographically segmented into North America, Europe, Asia-Pacific, and Rest of the World.
Some of the key players in the market are:
What the Report Offers